Ram Pradhum, Shah Samir, Patel Brijesh, Osman Mohammed, Bhatt Kunal, Jaber Wissam, Shah Mahek
Division of Cardiology, Emory University Hospital, Atlanta, GA, United States of America.
Department of Medicine, Albert Einstein Medical Center, Philadelphia, PA, United States of America.
Int J Cardiol. 2023 Jan 15;371:121-125. doi: 10.1016/j.ijcard.2022.08.057. Epub 2022 Sep 6.
For patients with refractory heart failure despite optimal medical therapy, orthotopic heart transplantation (OHT) remains the treatment of choice. Since transplanted hearts have variable cardiac denervation and acute coronary syndrome often presents as a silent myocardial infarction or with atypical symptoms, the true impact of ACS on outcomes within this population needs more study. The aim of this study is to evaluate in-hospital mortality in post-transplant patients with ACS.
Utilizing data from the 2002-15 Nationwide Inpatient Sample database, patients with a primary diagnosis of acute coronary syndrome among those with prior heart transplantation were included. A risk adjusted regression analysis was performed to assess if ACS post-OHT had an independent impact on the risk of in-hospital mortality. A 2:1 propensity matching was used to match ACS patients with and without OHT, respectively to assess differences in mortality.
A total of 3,224,073 patients with a primary diagnosis of acute coronary syndrome were included, of which 842 (0.03%) were heart-transplant recipients. The type of ACS: NSTEMI (76.0% vs 74.5%; p = 0.32) and STEMI (24.8% vs 26.7%; p = 0.21) between heart transplant and non-heart transplant patients was similar in both groups. Following ACS, patients with heart transplant were more likely to have accompanying shock of any etiology (15.6% vs 3.8%; p < 0.001) and cardiogenic shock (11.2% vs 2.6%; p < 0.001) compared to those with native hearts. OHT patients also had significantly higher in-hospital mortality (14.3% vs. 3.7%; p < 0.001) that remain significant following regression analysis (aOR 3.6, 95% CI 2.8-4.5; p < 0.001) irrespective of the presence of cardiogenic shock compared to native hearts. This relationship remained consistent following propensity matching where patients with OHT had significantly higher in-hospital mortality (13.5% vs. 7%; p < 0.001).
ACS following OHT was more likely to have accompanying cardiogenic shock. ACS in the setting of prior OHT remained a strong independent predictor of higher mortality as compared to native hearts.
对于尽管接受了最佳药物治疗仍患有难治性心力衰竭的患者,原位心脏移植(OHT)仍然是首选治疗方法。由于移植心脏的心脏去神经支配情况各不相同,且急性冠状动脉综合征常表现为无症状性心肌梗死或伴有非典型症状,因此急性冠状动脉综合征(ACS)对该人群预后的真正影响需要更多研究。本研究的目的是评估移植后发生急性冠状动脉综合征患者的住院死亡率。
利用2002 - 2015年全国住院患者样本数据库中的数据,纳入既往有心脏移植病史且初步诊断为急性冠状动脉综合征的患者。进行风险调整回归分析,以评估心脏移植术后的急性冠状动脉综合征是否对住院死亡风险有独立影响。采用2:1倾向评分匹配法,分别将有和没有进行心脏移植的急性冠状动脉综合征患者进行匹配,以评估死亡率的差异。
共纳入3224073例初步诊断为急性冠状动脉综合征的患者,其中842例(0.03%)为心脏移植受者。心脏移植患者与非心脏移植患者的急性冠状动脉综合征类型:非ST段抬高型心肌梗死(NSTEMI)(76.0%对74.5%;p = 0.32)和ST段抬高型心肌梗死(STEMI)(24.8%对26.7%;p = 0.21)在两组中相似。发生急性冠状动脉综合征后,与有天然心脏的患者相比,心脏移植患者更易伴有任何病因的休克(15.6%对3.8%;p < 0.001)和心源性休克(11.2%对2.6%;p < 0.001)。心脏移植患者住院死亡率也显著更高(14.3%对3.7%;p < 0.001),回归分析后仍具有显著性(校正比值比3.6,95%可信区间2.8 - 4.5;p < 0.001),无论是否存在心源性休克,与有天然心脏的患者相比皆是如此。倾向评分匹配后这种关系仍然一致,心脏移植患者住院死亡率显著更高(13.5%对7%;p < 0.001)。
心脏移植术后发生的急性冠状动脉综合征更易伴有心源性休克。与有天然心脏的患者相比,如果之前进行过心脏移植,急性冠状动脉综合征仍然是较高死亡率的有力独立预测因素。